Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 12

Identification of thyroxine-binding globulin as a candidate plasma marker of chronic obstructive pulmonary disease

Authors Diao W, Shen N, Du Y, Sun X, Liu B, Xu M, He B

Received 23 March 2017

Accepted for publication 26 April 2017

Published 25 May 2017 Volume 2017:12 Pages 1549—1564

DOI https://doi.org/10.2147/COPD.S137806

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Charles Downs

Peer reviewer comments 2

Editor who approved publication: Dr Richard Russell

Wenqi Diao,1 Ning Shen,1 Yipeng Du,1 Xiaoyan Sun,1 Beibei Liu,1 Ming Xu,2,3 Bei He1

1Department of Respiratory Medicine, 2Department of Cardiology, Institute of Vascular Medicine, Peking University Third Hospital, 3Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing, People’s Republic of China

Abstract: Biomarkers for the management of chronic obstructive pulmonary disease (COPD) are limited. The aim of this study was to explore new plasma biomarkers in patients with COPD. Thyroxine-binding globulin (THBG) was initially identified by proteomics in a discovery panel and subsequently verified by enzyme-linked immunosorbent assay in another verification panel with a 1-year follow-up. THBG levels were elevated in patients with COPD (9.2±2.3 µg/mL) compared to those of the controls (6.6±2.0 µg/mL). Receiver operating characteristic curves suggested that THBG was able to slightly differentiate between patients with COPD and controls (area under the curve [AUC]: 0.814) and performed better if combined with fibrinogen (AUC: 0.858). THBG was more capable of distinguishing Global Initiative for Obstructive Lung Disease stages I–III and IV (AUC: 0.851) compared with fibrinogen (AUC 0.582). THBG levels were negatively associated with predicted percentage forced expiratory volume in 1 s and positively related to predicted percentage residual volume, RV/percentage total lung capacity, and percentage low-attenuation area. COPD patients with higher baseline THBG levels had a greater risk of acute exacerbation (AE) than those with lower THBG levels (P=0.014, by Kaplan–Meier curve; hazard ratio: 4.229, by Cox proportional hazards model). In summary, THBG is a potential plasma biomarker of COPD and can assist in the management of stable stage and AEs in COPD patients.

Keywords:
thyroxine-binding globulin, biomarker, chronic obstructive pulmonary disease, proteomics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Characterization of throat microbial flora in smokers with or without COPD

Diao W, Shen N, Du Y, Qian K, He B

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1933-1946

Published Date: 4 July 2017